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Abstract
Purpose—To describe a method for quantitatively dealing with drug dose in comparative
effectiveness reviews. Second-generation antidepressants are used as an example to illustrate this
method, and to determine whether dose influences conclusions on comparative effectiveness.
Methods—Studies previously identified in a systematic review of second-generation
antidepressants were included if data on drug dose were available. The usual dosing range for each
drug was defined, and then used to create 2- and 3-level dose categories. Placebo-controlled data
were used to calculate overall effect sizes for the drug class and effect sizes stratified by drug dose.
Meta-regression tested the impact of dose on effect size. Weighted mean differences and risk ratios
were calculated for comparative studies, stratifying by whether compared doses were equivalent.
Results—The dose classification method was able to identify dose-response trends in the context
of meta-analysis. Compared to low dose studies, medium and high dose studies had a 1 to 2 point
greater differential in mean HAM-D change (P<0.001). Dose was not a statistically significant
predictor of categorical HAM-D response. Among comparative trials with non-equivalent doses,
trends favored higher dose categories, but generally were not statistically significant.
Conclusions—A structured method for quantitatively dealing with drug dose in comparative
effectiveness reviews is described, with application to the second-generation antidepressants. Dose-
dependent reductions in HAM-D scores were identified, although differences did not translate into
better response rates for higher doses. Dose equivalency was not a significant factor among
comparative studies in second-generation antidepressants.
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An abundance of information about existing and emerging health care interventions is readily
available, posing challenges for clinicians, patients and researchers to determine the best
available treatment at a given time.1 Among methods for assessing the comparative
effectiveness of health care interventions, systematic reviews are an important tool for
enhancing the ability of health care professionals to interpret and apply research evidence in a
timely manner.2, 3 Meta-analysis – the statistical analysis of the results from multiple
independent studies – is a useful method for increasing statistical power and the precision of
the estimate of treatment effect.4 Systematic review and meta-analysis have been widely used
in comparing different pharmaceutical treatments, as exemplified by the Cochrane
Collaboration, the Agency for Healthcare Research and Quality, and the Drug Effectiveness
Review Project.
Although systematic review and meta-analysis are valuable for comparing effects of different
medications, conclusions are often limited by available evidence. One problem unique to
pharmaceutical comparisons is the issue of drug dose. When comparing the benefits or harms
of one treatment to another, comparable doses rarely are defined. Clinicians generally have a
sense of how the dose of one drug compares to the dose of an alternative drug, although these
distinctions usually are not evidence-based. This often leads to concerns as to whether
differences – or lack of differences – in comparative effectiveness are related to drug dose.
Considering second-generation antidepressants, for example, a general rule of thumb may be
that fluoxetine 20mg is roughly equivalent to sertraline 100mg or escitalopram 10mg. If this
rule of thumb is true and we compare these drugs at equivalent doses, we assume that any
differences in comparative effectiveness are attributed to the drug rather than the drug dose.
However, how do you interpret the results of a study that compares non-equivalent doses such
as fluoxetine 20mg, sertraline 200mg, and escitalopram 20mg? In the same regard, looking
across studies or combining data from differently designed studies, can anything be said about
the effect size of fluoxetine compared to the effect sizes of sertraline or escitalopram if relative
drug doses differed?
This example presents several problems. First, we assume that increases in drug dose are related
to an increased effectiveness, indicating a positive dose-response relationship. A clear dose-
response relationship is well established for some drug classes (e.g., inhaled corticosteroids
follow a logarithmic dose-response curve),5,6 but is less clear for other drug classes such as
the antidepressants. Second, there is a general lack of standardized dosing guidelines for
assessing the comparative effectiveness of different drugs within the same therapeutic class.
Clinicians generally have a sense of how doses of different drugs within the same class
compare, but universally accepted comparative dosing evidence is not available for most drugs.
Mechanisms such as the World Health Organization’s Defined Daily Dose exist, but this
establishes an average therapeutic dose rather than a range of comparable doses. Third, methods
to handle drug dose in comparative effectiveness studies are not well developed. Most
systematic reviews and meta-analyses handle the issue of drug dose qualitatively – narratively
describing differences. Quantitative methods for dealing with dose differences include
stratification7,8 and meta-regression.9 Stratification allows for comparison of the relative risk
or odds ratio across dosing levels while meta-regression explores the influence of dose on the
effect size across trials. Still, these methods assume that some form of comparative dose
equivalence guideline exists and require that a sufficient number of eligible studies exist for
analysis. Unfortunately for researchers and health care professionals, studies using such
methods are the exception rather than the norm.
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The purpose of this paper is to illustrate a dose classification method for quantitatively
addressing if drug dose is an important factor to consider in a meta-analysis. We base our
discussion on the analysis of studies previously identified by a systematic review of the
comparative effectiveness of second-generation antidepressants. Our specific objectives are:
1. to describe a simple method for detecting inequalities in dose when comparing across
different drugs in the same therapeutic class,
2. to describe the relationship between dose and effect size for second-generation
antidepressants, and
3. to determine whether the comparative effectiveness of second-generation
antidepressants is related to differences in drug dose.
METHODS
Comparative Doses
In comparing doses across drugs, we first defined a usual dosing range for each drug. This
range initially was based on U.S. Food and Drug Administration (FDA) labeled dosing
recommendations. Because the FDA-approved range does not necessarily capture the spectrum
of doses used in clinical practice or represented in clinical studies,10, 11–12 we examined the
lower and upper bounds of this range carefully. As a result, the upper bound for duloxetine
was increased to 120mg/day,13,14 and the lower bound for some drugs (e.g., immediate release
bupropion, fluoxetine, and paroxetine) was decreased. Using this modified dosing range, we
then defined cut-points to create a two- and three-level dose classification system (Table 1).
The two-level classification system defined high doses as greater than the midpoint of the
range; low doses encompassed doses at or below the midpoint of the range. The three-level
classification system defined cut-points using the lower and upper 25th percentiles of the range;
low doses were below the 25th percentile of the range, medium doses were greater than or equal
to the 25th percentile but less than or equal to the 75th percentile of the range, and high doses
were greater than the 75th percentile of the range. Because some studies defined doses outside
of our pre-specified ranges, we defined doses smaller than the low dose boundary of the range
as low, and doses greater than the upper boundary of the range were included in the high dose
category. More finite cut-points (e.g., 4-level or 5-level) also were considered, although we
realized that a dose classification method needed to capture realistic dose differences from a
clinician’s perspective, and sufficient evidence must be available to make realistic comparisons
for each dose level.
Some clinical trials define fixed drug doses, while other studies allow clinicians to increase or
decrease doses based on clinical response and side effects (i.e., flexible dosing). Although
meta-analytic methods considering the effect of drug dose would ideally be limited to fixed
dose trials,9 we were concerned that focusing only on fixed dose trials would have limited
application in comparative effectiveness reviews. Thus, we included flexible dose trials and
defined the dose category based on the mean dose used among trial participants. We tested for
potential regression to the mean among flexible dosing studies by conducting a sensitivity
analysis that excluded flexible dose trials.
Study Eligibility
We analyzed randomized controlled trials that compared one second-generation antidepressant
to another or to placebo. Trials had to be 1) at least 6 weeks in duration, 2) report a fixed dose
or a mean dose (i.e., for flexible dose trials), 3) assess treatment effect using the Hamilton
Depression Rating Scale (HAM-D), 4) have a mean population age ≤ 65 years, and 5) conducted
primarily in outpatients. We excluded relapse or recurrence prevention studies, as well as
studies that were conducted in patients with mild or subsyndromal depression (defined by a
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mean baseline HAM-D < 18). Studies conducted in special populations (e.g., HIV, Substance
Abuse Disorder, etc.) also were excluded.
Data Abstraction
For each trial we abstracted the drug, dose, duration, mean age of participants, mean and
standard deviation for the baseline, endpoint, and change in the HAM-D, and the number of
randomized participants characterized as a responder at endpoint. Only studies that defined
response as ≥ 50% improvement in HAM-D score from baseline to endpoint were included in
the responder analysis. The standard deviation for the mean HAM-D change was recorded
when available; for trials that did not report a standard deviation for the mean change, we
imputed a standard deviation using the mean of the standard deviations from trials that had a
similar sample size and baseline HAM-D scores.
Dose and Effect Size
The goal of this analysis was to illustrate the influence of dose on effect size estimates in the
context of meta-analysis. Studies were included if they compared active treatment to placebo
using the mean HAM-D change as a continuous variable or a count of the number of responders
as a binary variable. For studies that compared more than one active treatment to placebo, both
drug-placebo comparisons were included, but the sample size of the placebo arm was reduced
proportionately for each comparison so as not to double count the placebo group. We conducted
stratified meta-analysis for HAM-D change and responder status to obtain pooled estimates
for each dose category (2-level = low and high; 3-level = low, medium, and high). For the mean
HAM-D change, we pooled the weighted mean differences between active treatment and
placebo for each dose stratum. For the analysis of responders versus non-responders, the natural
log risk ratios were used to estimate a pooled risk ratio within each dose stratum.
We then pooled all of the studies in a meta-regression to assess the impact of dose on the
differences in HAM-D and risk ratios. For the two-level dosing scheme, high dose was
compared to low dose. The 3-level dosing scheme compared medium dose to low dose and
high dose to low dose. For these analyses we assumed that individual drugs do not differ
substantially,15,16 but still controlled for the effect of drug in the meta-regression. Between-
study variance was compared for each model by looking at changes in tau^2.
Comparative Effectiveness for Equivalent vs. Non-Equivalent Doses
To assess whether dose influences conclusions regarding the comparative effectiveness of
second-generation antidepressants, we included randomized trials that compared one second-
generation antidepressant to another. Studies were stratified by whether they compared
equivalent or non-equivalent doses. For non-equivalent doses in the 3-level dose classification,
we treated the lower of the two doses as the reference group (i.e., medium compared to low,
high compared to low, or high compared to medium). Meta-analysis of the binary response
outcome and weighted mean difference in HAM-D change were conducted first for all
comparative trials, and then for the equivalent and non-equivalent dose strata for the 2- and 3-
level dose classification systems.
All meta-analyses used a random effects model. Heterogeneity among trial was quantified
using I2,17,18 which measures the percentage of inconsistency across studies that is due to
heterogeneity. Individual studies were not removed from the analysis based on their apparent
contribution to heterogeneity. All analyses were conducted using the “metan” and “metareg”
commands installed in Stata 9.1 (StataCorp, College Station, TX).
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Of the 94 head-to-head and 64 placebo-controlled trials included in the initial systematic
review,16 74 studies were eligible for this analysis (Figure 1). Among these, 34 provided data
for a head-to-head comparison and 46 provided placebo-controlled data. Six studies
contributed both a head-to-head comparison and one or more placebo comparisons. All second-
generation antidepressants included in our analysis were represented by at least one placebo-
controlled study, although some drugs (e.g., escitalopram and mirtazapine) were represented
by fewer studies than others (Table 2). Among included head-to-head trials, many possible
drug-drug comparisons were not represented. All comparisons included at least one SSRI; no
studies comparing an SNRI to an SNRI or an SNRI to an “other” drug were eligible for inclusion
(Table 3).
Placebo-Controlled Data
Weighted mean difference in HAM-D scores—The weighted mean difference in HAM-
D change between active treatment and placebo was calculated for all studies, and then
separately for each stratum of the 2- and 3-level dose classification system (Figure 2). Overall,
the inference drawn from all studies was similar to inferences drawn from each dose stratum.
Still, we found a larger difference for higher doses, especially when using the 3-level dose
classification. The 2-level classification showed a small trend favoring higher doses, although
confidence intervals for the pooled estimates were overlapping for the low and high dose
stratum. The meta-regression confirmed the dose-response trends illustrated in Figure 2, even
after controlling for drug. For the 3-level dose classification, the weighted mean difference in
HAM-D scores was 1.6 points larger for medium dose compared to low dose (95% CI: −2.2
to −0.9), and 2.3 points larger for high dose compared to low dose (95% CI: −3.4 to −1.2). The
difference in HAM-D scores was 0.7 HAM-D points greater for high dose compared to low
dose in the 2-level classification after controlling for drug (95% CI: −1.5 to 0.1). The estimated
between-study variance (tau^2) was reduced from 0.77 to 0.39 in the 3-level model, but did
not change significantly in the 2-level model. These findings were similar in the sensitivity
analyses, where only fixed dose studies were included (data not shown).
Responder analysis—Risk ratios – ratios reflecting the likelihood of HAM-D response for
active treatment over the likelihood for placebo – were calculated for all studies and then
separately for the 2- and 3-level dose strata (Figure 3). Consistent with the analysis of mean
HAM-D change, inference drawn from all studies was generally similar to inferences drawn
from each dose stratum. The risk ratios were larger for higher dose categories compared to
lower dose categories, suggesting better efficacy for higher doses. However, these trends were
not statistically significant. In the meta-regression controlling for drug, the 3-level dose
classification risk ratio was 0.08 larger for medium dose compared to low dose (95% CI: −0.2
to 0.4) and 0.13 larger for high dose compared to low dose (95% CI: −0.4 to 0.6). In the meta-
regression for the 2-level dose classification, the risk ratio for high dose was 0.1 higher than
low dose (95% CI: −0.2 to 0.4), again controlling for drug. The estimated between-study
variance (tau^2) did not change significantly when adding the 3-level or 2-level dose variables
to the model. The sensitivity analysis of only fixed dose studies revealed similar trends (data
not shown).
Head-to-Head Data
Mean difference in HAM-D scores—The overall weighted mean difference in HAM-D
change was approximately the same (−0.1; 95% CI: −0.4 to 0.2) between arms of comparative
trials. When trials were separated by whether equal doses were compared using the 3-level
dose classification (Figure 4), the weighted mean difference in HAM-D change between active
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treatments was not statistically significantly different from zero for equivalent dose studies
(−0.02; 95% CI: −0.4 to 0.4), nor for non-equivalent dose studies (0.4; 95% CI: −0.3 to 1.1).
However, the point estimate favored the higher dose treatment arms, illustrating the potential
over estimation of effect size when compared doses were not equivalent. The same was true
using the 2-level dose classification for equivalent dose studies (0.2; 95% CI −0.2 to 0.6).
Higher dose arms showed more change in the HAM-D than lower dose arms in the non-
equivalent dose studies (0.7; 95% CI: 0.1 to 1.2). In other words, high dose comparators had
nearly a 1-point larger reduction in HAM-D scores than lower dose comparators.
Responder analysis—The comparative trials showed similar response rates between arms
(RR=0.99; 95% CI: 0.94 to 1.03). When studies were stratified by whether they compared
equivalent or non-equivalent doses (Figure 5), risk ratios again did not differ significantly from
1.0. This finding was consistent for the 3-level and 2-level classification method. The point
estimate favored the higher doses for the 2-level classification, again illustrating the potential
over estimation of effect size when compared doses were not equivalent.
Consistency of Effects across Studies
Heterogeneity of treatment effects (i.e., I2) generally was low to moderate18 across studies,
even after stratifying by dose. The largest heterogeneity was detected for the analysis of
comparative trials with non-equivalent doses, particularly with the 3-level dose classification.
The number of constituent trials was relatively small for these dose strata.
DISCUSSION
Evaluating the dose-response relationship for a single drug is relatively straightforward, but
comparing across different therapeutic agents with different relative doses is a more
complicated endeavor. With the exception of therapeutic classes that have physiologic data
available to define comparable doses, previous meta-analyses evaluating the effect of drug
dose have used ad hoc methods to define doses, or have ignored dose completely. We
demonstrate a structured method for use in meta-analysis to account for inequalities in drug
doses across different therapeutic agents. This method is based on the usual dosing range of
constituent agents within the selected drug group, with structured cut-points to define dose
levels. Our method does not treat a single drug in the therapeutic group as a reference drug, as
with some previous meta-analyses (e.g., haloperidol equivalents19 and imipramine-
equivalents20). Our method also does not require researchers conducting systematic reviews
to extensively analyze the dose-response relationship for individual agents.21 Instead, we
assume that the dosing range established by phase I-III trials and reported in product labeling
provides an adequate balance among safety, tolerability, and efficacy. We also assume that
deviations in these dosing recommendations will be reflected in clinical guidelines and
prescribing behavior. We believe that our method allows for straightforward and generalized
application in comparative effectiveness reviews, and is likely to capture gross inequalities in
comparing different doses of different treatments.
Using second-generation antidepressant as an example, we found that both a 2- and 3-level
dose classification system were able to identify dose-response trends in the context of meta-
analysis. For active treatment compared to placebo, the weighted mean difference in HAM-D
change varied across doses, with slightly larger improvements at higher doses. Dose trends
also were identified in the risk ratio analysis of HAM-D response, although the risk ratio
confidence intervals were generally overlapping among dose categories. Among comparative
trials with non-equivalent doses, the weighted mean difference in HAM-D change favored
higher doses, but was statistically significant only for the 2-level dose classification. Overall,
the 3-level classification was more sensitive than the 2-level classification for detecting
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differences in effect size. The 3-level classification also is less likely to be influenced by dose
misclassification compared with the 2-level classification. Still, the 2-level classification may
have utility for reviews that identify too few studies to create 3 dose strata.
Even though we observed an average 1-2 HAM-D point improvement in response for
incremental increases in dose, the dose-response curve was relatively flat. This may be partially
related to the strong placebo effect observed in antidepressant trials.22 The relatively small
differences in the change in HAM-D that we identified across dose strata are likely not clinically
significant. This is consistent with the fact that the likelihood of actually responding to the drug
as defined by the change in the HAM-D did not differ significantly across dose strata. Although
this could be related to the sensitivity of our dose classification method, it is generally consistent
with the small incremental improvements in efficacy previously demonstrated with
antidepressants.11–12, 23 Our analysis also is consistent with previous studies in that we found
the effect size for low dose studies to be the most disparate from other evidence (i.e., using the
3-level classification in Figure 2). This parallels the findings of a meta-analysis of first-
generation antidepressants that converted drugs to imipramine-equivalent doses and concluded
that higher doses did not provide increased efficacy, but that the low doses showed a reduction
in efficacy.20
In the context of the effectiveness of second-generation antidepressants, we found that drug
dose does not significantly influence the evidence base for clinical decision-making. Still, this
analysis does not support ignoring dose in other comparative effectiveness reviews. Instead,
we advocate for testing our method in other therapeutic areas. In particular, we believe this
method should be tested among drug classes that have a clear dose-response relationship. In
such a case, we believe our method could help differentiate equivalent dose from non-
equivalent dose trials, and help in interpretation of the evidence base. Furthermore, we did not
explore the relationship between dose and adverse events. Given that clinicians need to balance
evidence of effectiveness with harms, this is an important unanswered question. In fact,
evidence from a recent meta-analysis of rare but harmful effects of anti-TNF drugs illustrates
this point.8 The overall results of their analysis revealed a significant risk of malignancy and
infection. When stratified by dose, however, these risks were found to be significantly greater
among high dose regimens; ignoring dose would have led the authors to different conclusions.
Limitations
Our dose classification method is relatively easy to use for comparing the effectiveness of
diverse medications, but it requires that sufficient evidence is available to allow for
stratification. Ideally, we would have limited our analysis to dose comparisons conducted
within studies, rather than between studies. Data were insufficient in quantity to limit evidence
to this type of design. Furthermore, in examining the relationship between dose and effect size,
we assumed that individual drugs did not differ significantly,15,16 and that unadjusted
differences in effect size were related to dose rather than drug. To support this, our overall
pooled risk ratio (RR=1.01; 95% CI 0.97 to 1.06) was generally similar to risk ratios from
individual drug comparisons (e.g., fluoxetine vs. paroxetine RR = 1.09 (95% CI 0.99 to 1.21);
fluoxetine vs. sertraline RR = 1.11 (95% CI 1.01 to 1.21).16 Still, we controlled for drug in
our meta-regression and found the dose-effect to be of comparable magnitude to the unadjusted
values. In comparative assessments that pooled data across multiple different comparisons, it
is feasible that the random order in which drugs were included in the analysis could affect the
overall pooled estimate. To test whether this was apparent in our analysis, we randomly
shuffled the order of drug comparisons multiple times and compared the pooled estimates.
Although the pooled estimates were very similar, it is still possible that some remaining drug-
specific effect biases our conclusions.
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Because our method is rooted in dosing ranges approved by regulatory authorities, it is
dependent on initial dose-ranging trials required for approval. These trials, and the ultimate
dosing recommendations reported in product labeling, reflect a balance among safety,
tolerability, and efficacy. It is possible that this dosing range might not fully capture the dose
response curve for different drugs, thus introducing potential misclassification bias for our
method. We closely evaluated the upper and lower limits of approved doses and modified the
range based on other evidence, known clinical practice patterns, and our own clinical
assessment. In the end, the dosing range that we used to define dose categories has some degree
of subjective assessment. Finally, it is generally recommended to exclude flexible dose studies
when conducting meta-regression on the effect of dose.9 We included the mean dose from
flexible-dose studies, but conducted a sensitivity analysis to determine whether this
significantly impacted our conclusions. Excluding the flexible-dose data did not influence our
results. Still, the potential biases that occur when doses are titrated to effect or adjusted
downward based on tolerability should not be disregarded.
CONCLUSIONS
We present a structured method for use in meta-analysis to account for inequalities in doses
across different therapeutic agents used to treat the same condition. Using this method, we
illustrate the relationship of second-generation antidepressant dose with estimates of effect
size, and demonstrate that only minimal differences exist among agents across comparative
trials – even in studies that compared non-equivalent doses. We advocate for the use of this
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QUOROM flow diagram for dose analysis
* Studies that included both head-to-head and placebo comparisons were included in both
analyses (n = 6)
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Weighted mean difference in HAM-D change for placebo-controlled trials stratified by dose
* The number of comparisons differs from the number of articles included in the systematic
review because some studies contributed more than one placebo-controlled comparison, and
some studies contributed data to the responder analysis but not the HAM-D change analysis
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Risk ratio for placebo-controlled trials stratified by dose
* The number of comparisons differs from the number of articles included in the systematic
review because some studies contributed more than one placebo-controlled comparison, and
some studies contributed data to the HAM-D change analysis but not the responder analysis
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Difference in weighted mean HAM-D change for comparative trials stratified by dose
equivalence
* The number of comparisons differs from the number of articles included in the systematic
review because some studies contributed multiple dosing arms for an active comparator, and
some studies contributed data to the HAM-D change analysis but not the responder analysis
† Only applicable to non-equivalent dose comparisons
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Risk ratio for comparative trials stratified by dose equivalence
* The number of comparisons differs from the number of articles included in the systematic
review because some studies contributed multiple dosing arms for an active comparator, and
some studies contributed data to the responder analysis but not the HAM-D change analysis
† Only applicable to non-equivalent dose comparisons
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